HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.16
+0.96 (6.76%)
Nov 6, 2026, 4:00 PM EST - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,790 employees as of June 30, 2026.
Employees
1,790
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$306,772
Profits / Employee
$9,991
Market Cap
2.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,790 | - | - |
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Xeris Biopharma Holdings | 435 |
| BioCryst Pharmaceuticals | 435 |
HCM News
- 2 days ago - HUTCHMED (China) Transcript: Fireside chat - Transcripts
- 2 days ago - HUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic Anemia - Nasdaq
- 2 days ago - Hutchmed says sovleplenib granted FDA orphan drug designation - TheFly
- 2 days ago - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia - GlobeNewsWire
- 5 days ago - HUTCHMED Advances ORPATHYS-TAGRISSO Through EU, Japan Reviews - Nasdaq
- 5 days ago - Hutchmed announces filings for Orpathys accepted for review in Japan, Europe - TheFly
- 5 days ago - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan - GlobeNewsWire
- 9 days ago - HUTCHMED (China) Limited Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia - Nasdaq